Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 8/20 | 0.51 |
| ▸ | HCK | P08631 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | CSK | P41240 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268628 | 0.87 | SRC (0.53) | BTKSRCHCKLCKABL1 | |
| SCHEMBL18269002 | 0.85 | FGFR2 (0.62) | BTKLCKEGFRKDR | |
| SCHEMBL15613536 | 0.85 | BTK (0.50) | BTKSRCHCKLCKABL1 | |
| SCHEMBL18269159 | 0.85 | TGFBR1 (0.52) | BTKKCNH2 | |
| SCHEMBL18269038 | 0.85 | BTK (0.53) | BTKKCNH2LCKEGFR | |
| SCHEMBL15613564 | 0.84 | BTK (0.49) | BTKSRCHCKLCKABL1 | |
| SCHEMBL15613533 | 0.84 | BTK (0.49) | BTKSRCHCKLCKABL1 | |
| SCHEMBL18268991 | 0.84 | BTK (0.55) | BTKSRCHCKLCKABL1 | |
| SCHEMBL18269007 | 0.83 | SRC (0.57) | BTKSRCHCKLCKABL1 | |
| SCHEMBL18268652 | 0.83 | BTK (0.55) | BTKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | PHARMASCIENCE INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| WO-2016187723-A1 | INHIBITORS OF THE TEC KINASE ENZYME FAMILY | PHARMASCIENCE INC. (CA) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179210-A1 | Inhibitors of the TEC Kinase Enzyme Family | TEC, BTK, LCK | BTK 2/4885KCNH2 4256/4885SRC 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.